These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30904724)

  • 1. The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies.
    Neumann R; Barequet D
    Drug Discov Today; 2019 Aug; 24(8):1433-1435. PubMed ID: 30904724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomaterials for ocular drug delivery.
    Liu S; Jones L; Gu FX
    Macromol Biosci; 2012 May; 12(5):608-20. PubMed ID: 22508445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.
    Subrizi A; Del Amo EM; Korzhikov-Vlakh V; Tennikova T; Ruponen M; Urtti A
    Drug Discov Today; 2019 Aug; 24(8):1446-1457. PubMed ID: 30738982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery.
    Bhattacharjee A; Das PJ; Adhikari P; Marbaniang D; Pal P; Ray S; Mazumder B
    Eur J Ophthalmol; 2019 Jan; 29(1):113-126. PubMed ID: 29756507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein conjugates and fusion proteins as ocular therapeutics.
    Mehta SC; Kelley RF; Tesar DB
    Drug Discov Today; 2019 Aug; 24(8):1440-1445. PubMed ID: 31202674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular drugs and drug delivery systems - Current trends and future perspectives.
    Rupenthal ID; Daugherty AL
    Drug Discov Today; 2019 Aug; 24(8):1425-1426. PubMed ID: 31330186
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in ocular drug delivery.
    Rawas-Qalaji M; Williams CA
    Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2019; 35(1):1-2. PubMed ID: 30566384
    [No Abstract]   [Full Text] [Related]  

  • 12. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 14. The safety evaluation of long-acting ocular delivery systems.
    Thackaberry EA; Lorget F; Farman C; Bantseev V
    Drug Discov Today; 2019 Aug; 24(8):1539-1550. PubMed ID: 31173909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled and continuous release ocular drug delivery systems: pros and cons.
    Abdelkader H; Alany RG
    Curr Drug Deliv; 2012 Jul; 9(4):421-30. PubMed ID: 22640036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in ophthalmic drug delivery.
    Morrison PW; Khutoryanskiy VV
    Ther Deliv; 2014 Dec; 5(12):1297-315. PubMed ID: 25531930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic drug discovery.
    Clark AF; Yorio T
    Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.